Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of HIP1503 vs HGP1103 in Healthy Males
NCT02940314Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Mar 2016
- Primary completion
- May 2016
- Modality
- Orthosteric Ligands
01
Overview
Phase 1, randomised, open-label trial of solifenacin in overactive bladder (OAB) (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration at 72 hours and Maximum Plasma Concentration at 72 hours. Started Mar 2016; status: completed.
02
Drugs
solifenacin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT02940314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02940314.